| scholarly article | Q13442814 |
| P50 | author | Amalia Gastaldelli | Q43294287 |
| Ralph A. DeFronzo | Q58689309 | ||
| P2093 | author name string | Carolina Solis-Herrera | |
| Eugenio Cersosimo | |||
| Geoffrey D Clarke | |||
| Muhammad Abdul-Ghani | |||
| Patricia Iozzo | |||
| Robert J Chilton | |||
| Aurora Merovci | |||
| Sandra Martinez | |||
| Marjorie Molina-Wilkins | |||
| P2860 | cites work | Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes | Q26866924 |
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus | Q33786881 | ||
| Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 | Q33880303 | ||
| Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors | Q33960919 | ||
| MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial | Q33966645 | ||
| Glucose clamp technique: a method for quantifying insulin secretion and resistance | Q34191986 | ||
| Thiazolidinediones | Q34346862 | ||
| Body surface area in normal-weight, overweight, and obese adults. A comparison study | Q34503275 | ||
| Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance | Q34577169 | ||
| Diabetes and atherosclerosis: epidemiology, pathophysiology, and management | Q34646074 | ||
| Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma | Q35536451 | ||
| Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association | Q35615572 | ||
| Linking gene expression to function: metabolic flexibility in the normal and diseased heart | Q35807737 | ||
| Safety of PPAR agonists | Q36783775 | ||
| Diabetic cardiomyopathy revisited | Q36860318 | ||
| Pioglitazone after Ischemic Stroke or Transient Ischemic Attack | Q36953272 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion | Q37577126 | ||
| Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. | Q37577159 | ||
| Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy | Q38502148 | ||
| Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored | Q39209990 | ||
| Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study | Q42915280 | ||
| Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone | Q43584208 | ||
| Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. | Q43798802 | ||
| Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance | Q44155540 | ||
| Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus | Q44522162 | ||
| Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients | Q44527041 | ||
| Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone | Q45166060 | ||
| Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus | Q46059605 | ||
| Velocity-encoded cine MRI in the evaluation of left ventricular diastolic function: measurement of mitral valve and pulmonary vein flow velocities and flow volume across the mitral valve | Q46215308 | ||
| Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). | Q46552257 | ||
| Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption | Q46592677 | ||
| Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study | Q46670150 | ||
| CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. | Q47773960 | ||
| Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. | Q51466405 | ||
| Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. | Q51468950 | ||
| Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. | Q51470916 | ||
| Generation of myocardial factor images directly from the dynamic oxygen-15-water scan without use of an oxygen-15-carbon monoxide blood-pool scan | Q77424977 | ||
| P4510 | describes a project that uses | RStudio | Q4798119 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diastole | Q492905 |
| P304 | page(s) | 1530-1536 | |
| P577 | publication date | 2017-08-28 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes | |
| P478 | volume | 40 |
| Q92065614 | Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment |
| Q60572729 | Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance |
| Q90722135 | Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence |
| Q89624033 | From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options |
| Q58566731 | Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review |
| Q90575879 | Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease |
| Q91264430 | Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies |
| Q100946503 | Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors |
| Q42379243 | Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials |
| Q47697775 | Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors |
| Q61814333 | Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes |
Search more.